Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Multiple Locations, Japan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
Patients diagnosed with Alzheimer's Disease who are to be administered both donepezil hydrochloride and memantine hydrochloride in clinical practice.
Exclusion criteria:
Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
E2020
|
Initial dose of 3 mg orally once daily.
After 1-2 weeks, dosage increased to 5 mg orally once daily.
After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type.
Dose reduced appropriately according to patient's symptoms.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Investigations on adverse events and adverse drug reactions
Time Frame: Up to 12 months
|
Up to 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Severity of dementia based on the Functional Assessment Staging Test (FAST)
Time Frame: Baseline, Month 3, Month 6, and Month 12
|
FAST is a seven stage system based on level of functioning and daily activities.
It focuses more on an individual's level of functioning and activities of daily living versus cognitive decline
|
Baseline, Month 3, Month 6, and Month 12
|
|
Change From Baseline in the Mini-Mental State Examination (MMSE) Score
Time Frame: Baseline and Month 12
|
The MMSE is a brief 30-point questionnaire test that is used for the assessment of dementia patients' cognitive impairment.
Evaluation of points are as follows: 24 to 30 = no cognitive impairment, 18 to 23 = mild cognitive impairment, 0 to 17 = severe cognitive impairment.
Lower scores indicate worsening.
|
Baseline and Month 12
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Geriatric Medicine 55(1): 87-100, 2017.
- Geriatric Medicine 55(11): 1251-1264, 2017.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Alzheimer Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Enzyme Inhibitors
- Nootropic Agents
- Cholinesterase Inhibitors
- Donepezil
Other Study ID Numbers
Other Study ID Numbers
- ART07T
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.